Physician profile
Meghan Malone
NPI 1043395650
$3,879.92
in general payments reported to CMS, 2019-2025
25 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $272 · 2021: $78.35 · 2022: $552 · 2023: $794 · 2024: $689 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,357.89 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $456.75 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $240.82 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $208.42 | 2022-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.18 | 2019-2023 | Xifaxan, Trulance |
| Celgene Corporation | $152.02 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $150.91 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $143.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $142.49 | 2019-2022 | |
| Allergan, INC. | $135.01 | 2019 | |
| Janssen Scientific Affairs, LLC | $126.92 | 2023 | Stelara |
| Daiichi Sankyo INC. | $118.01 | 2019-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $69.36 | 2024-2025 | Dupixent |
| Portola Pharmaceuticals, LLC | $66.69 | 2019-2020 | |
| Braintree Laboratories, INC. | $58.30 | 2022-2023 | Sutab, Suflave |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $55.61 | 2020-2023 | Ocaliva |
| Ardelyx, INC. | $55.41 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $37.04 | 2022-2025 | Cre Pro |
| Shire North American Group INC | $34.37 | 2019 | |
| Olympus America INC. | $17.50 | 2024 | Endoclot Phs |
| Genzyme Corporation | $17.12 | 2025 | |
| Medtronic, INC. | $15.73 | 2024 | Interstim |
| Pfizer INC. | $13.78 | 2019 | |
| Endo Pharmaceuticals INC. | $13.46 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.88 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.